Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an update.
Ascletis Pharma Inc. announced promising results from its Phase Ib study of ASC30, an oral GLP-1 receptor agonist, at the European Association for the Study of Diabetes Annual Meeting. The study demonstrated significant weight reduction in participants with obesity and confirmed the drug’s safety and tolerability, with only mild to moderate gastrointestinal side effects. This development highlights Ascletis’ potential to impact the obesity treatment market positively and underscores its commitment to advancing effective therapeutic solutions.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a pharmaceutical company focused on developing innovative therapies, particularly in the field of metabolic diseases such as obesity. The company is known for its strong research and development capabilities, aiming to provide differentiated treatment options in its market sector.
Average Trading Volume: 8,566,753
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.67B
Learn more about 1672 stock on TipRanks’ Stock Analysis page.